会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom
    • 人分泌型IgA和IgM的合成以及从其形成药物
    • US08021645B2
    • 2011-09-20
    • US12138758
    • 2008-06-13
    • Michael R. SimonStephanie M. ChervinStephen C. Brown
    • Michael R. SimonStephanie M. ChervinStephen C. Brown
    • A61K49/00A61K39/02A61K39/08
    • C07K16/1282A61K2039/505C07K2317/21C07K2317/52C07K2317/76
    • A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
    • 提供了一种用于治疗受试者的组合物。 该组合物包括抗原特异性二聚体分泌型IgA和五聚体IgM治疗剂。 还提供了用于制备用于治疗人类艰难梭菌相关疾病的药物的方法,其中所述抗原特异性二聚体分泌型IgA和具有分泌成分的五聚体IgM的修饰形成抗原特异性二聚分泌型IgA和五聚体分泌型IgM治疗剂。 然后将抗原特异性二聚体分泌型IgA和五聚体分泌型IgM治疗剂与配制剂混合以产生胶囊,片剂,液体或栓剂给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。 还提供了用治疗剂进行艰难梭菌治疗的方法,其适于补充同时或之前的抗生素给药。
    • 9. 发明申请
    • SYNTHESIS OF HUMAN SECRETORY IgA AND IgM AND THE FORMATION OF A MEDICAMENT THEREFROM
    • 人类秘密IgA和IgM的合成及其药物的形成
    • US20080260822A1
    • 2008-10-23
    • US12138758
    • 2008-06-13
    • Michael R. SimonStephanie M. ChervinStephen C. Brown
    • Michael R. SimonStephanie M. ChervinStephen C. Brown
    • A61K9/48A61K39/44A61K9/28A61P31/04
    • C07K16/1282A61K2039/505C07K2317/21C07K2317/52C07K2317/76
    • A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
    • 提供了一种用于治疗受试者的组合物。 该组合物包括抗原特异性二聚体分泌型IgA和五聚体IgM治疗剂。 还提供了用于制备用于治疗人类艰难梭菌相关疾病的药物的方法,其中所述抗原特异性二聚体分泌型IgA和具有分泌成分的五聚体IgM的修饰形成抗原特异性二聚分泌型IgA和五聚体分泌型IgM治疗剂。 然后将抗原特异性二聚体分泌型IgA和五聚体分泌型IgM治疗剂与配制剂混合以产生胶囊,片剂,液体或栓剂给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。 还提供了用治疗剂进行艰难梭菌治疗的方法,其适于补充同时或之前的抗生素给药。